Table:
text: Alzheimer's disease research
Disease-modifying drug candidates
Disease-modifying candidates in late-stage clinical trials for Alzheimer's disease
Target_Approach Candidate_Name Trial_Phase Trial_Start_Date Expected_End_Date
Gamma Secretase Modulator/NSAID MPC-7869 Phase III Feb 2005 May 2008
Gamma Secretase Inhibitor LY451039 Phase III March 2008 March 2012
Antibody to Amyloid-Beta aab-001 Phase III Dec 2007 Dec 2010
Metal-Protein Interaction Attenuation PBT2 Phase II (completed) Dec 2006 Dec 2007
Fibrilization of Amyloid-Beta AZD-103 Phase II Dec 2007 May 2010
Neuroprotection AL-108 Phase II (completed) Jan 2007 Jan 2008
Brain Cell Apoptosis Inhibitor Dimebon Phase II (completed) Sept 2006 Nov 2007 (actual)
Natural Antibodies to A-Beta IVIg Phase II (completed) Feb 2006 June 2007
Vaccine to Amyloid-Beta acc-001 Phase II Nov 2007 Mar 2012
Notes Notes Notes Notes Notes

Question: What is the study start date if the candidate's name is Notes, for Alzheimer's research?

Question: What is the name of the candidate if the goal/approach in Alzheimer's research is "vaccine against amyloid-beta"?

Question: What is the testing phase if the expected end date is June 2007 for Alzheimer's research?

Question: What is the expected end date if the goal/approach is annotations in Alzheimer's research?

Question: What is the study start date if the name of the candidate in Alzheimer's research is PBT2?

Question: If the study start date is November 2007 for Alzheimer's research, what is the expected end date?